ETPrime

Piramal Pharma Share Price

  • 263.552.95 (1.14%)
  • Volume: 89,20,103
  • Live
  • Last Updated On: 18 Dec, 2024, 02:18 PM IST
STOCK SCORE
ETPrime Only
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...

Piramal Pharma Share Price

  • 263.552.95 (1.14%)
  • Volume: 89,20,103
Advertisment

Piramal Pharma share price insights

View All

  • In the last 2 years, only 3.54 % trading sessions saw intraday gains higher than 5 % .

  • Company's annual revenue growth of 14.23% outperformed its 3 year CAGR of 8.72%. (Source: Consolidated Financials)

  • 20 day moving crossover appeared yesterday. Average price gain of 4.24% within 7 days of this signal in last 5 years.

  • Company has spent 5.49% of its operating revenues towards interest expenses and 24.84% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

  • Piramal Pharma Ltd. share price moved up by 1.14% from its previous close of Rs 260.60. Piramal Pharma Ltd. stock last traded price is 263.55

    Share PriceValue
    Today/Current/Last263.55
    Previous Day260.60260.55

InsightsPiramal Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		767.72
    EPS - TTM
    (₹)    		0.34
    MCap
    (₹ Cr.)    		34,800.89
    Sectoral MCap Rank
    		17
    PB Ratio
    (x)    		4.37
    Div Yield
    (%)    		0.00
    Face Value
    (₹)    		10.00
    Beta

    Beta

    1 Month-
    3 Months-
    6 Months-
    1 Year-
    3 Years-

    		-
    VWAP
    (₹)    		264.68
    52W H/L
    (₹)
    307.90 / 114.35

    Piramal Pharma Share Price Returns

    1 Day1.14%
    1 Week2.01%
    1 Month4.69%
    3 Months14.89%
    1 Year108.18%
    3 YearsN.A.
    5 YearsN.A.

    ET Stock ScreenersTop Score Companies

    Check whether Piramal Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Piramal Pharma News & Analysis

    View all Piramal Pharma Share News & Announcements

    Piramal Pharma Share Analysis

    Unlock Stock Score, Analyst' Ratings & Recommendations

    Share Analysis Non Prime User
    • View Stock Score on a 10-point scale
    • See ratings on Earning, Fundamentals, Valuation, Risk & Price
    • Check stock performance
    JOIN ET PRIME

    Piramal Pharma Share Recommendations

    Recent Recos

    STRONG BUY

    Current

    Mean Recos by 6 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹245
    • OrganizationICICI Securities
    • ADD
    • Target₹180
    • OrganizationICICI Securities
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy3223
    Buy3332
    Hold----
    Sell----
    Strong Sell----
    # Analysts6555
    View all Stock Recommendations

    Piramal Pharma Financials

    • Insights

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 14.23% outperformed its 3 year CAGR of 8.72%. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent 5.49% of its operating revenues towards interest expenses and 24.84% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)
      Quarterly | AnnualSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
      Total Income2,302.861,970.682,578.742,020.081,960.57
      Total Income Growth (%)16.86-23.5827.663.049.70
      Total Expenses2,092.361,931.202,249.081,908.791,830.25
      Total Expenses Growth (%)8.35-14.1317.834.292.24
      EBIT210.5039.48329.66111.29130.32
      EBIT Growth (%)433.18-88.02196.22-14.60-
      Profit after Tax (PAT)22.59-88.64101.2710.115.02
      PAT Growth (%)--187.53901.68101.39-
      EBIT Margin (%)9.142.0012.785.516.65
      Net Profit Margin (%)0.98-4.503.930.500.26
      Basic EPS (₹)0.17-0.670.770.080.04
      Quarterly | AnnualSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
      Total Income1,390.771,099.961,578.491,057.251,083.32
      Total Income Growth (%)26.44-30.3249.30-2.4124.08
      Total Expenses1,085.11963.421,188.16950.17958.91
      Total Expenses Growth (%)12.63-18.9125.05-0.918.94
      EBIT305.66136.54390.33107.08124.41
      EBIT Growth (%)123.86-65.02264.52-13.93-
      Profit after Tax (PAT)210.0685.27273.0874.3477.16
      PAT Growth (%)146.35-68.77267.34-3.65-
      EBIT Margin (%)21.9812.4124.7310.1311.48
      Net Profit Margin (%)15.107.7517.307.037.12
      Basic EPS (₹)1.590.642.060.560.61
      Quarterly | Annual FY 2024 FY 2023 FY 2022
      Total Revenue8,346.557,306.666,834.90
      Total Revenue Growth (%)14.236.905.49
      Total Expenses8,163.967,474.186,393.87
      Total Expenses Growth (%)9.2316.9014.27
      Profit after Tax (PAT)17.82-186.46375.96
      PAT Growth (%)--149.60-54.98
      Operating Profit Margin (%)7.722.499.74
      Net Profit Margin (%)0.21-2.635.73
      Basic EPS (₹)0.14-1.573.19
      Quarterly | Annual FY 2024 FY 2023 FY 2022
      Total Revenue4,592.173,784.293,318.54
      Total Revenue Growth (%)21.3514.035.79
      Total Expenses4,084.553,653.642,881.84
      Total Expenses Growth (%)11.7926.7816.76
      Profit after Tax (PAT)391.2269.50343.05
      PAT Growth (%)462.91-79.74-39.97
      Operating Profit Margin (%)14.007.1515.84
      Net Profit Margin (%)8.912.0111.08
      Basic EPS (₹)3.050.582.91

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022
      Total Assets15,311.8114,522.5612,797.04
      Total Assets Growth (%)5.4313.4817.41
      Total Liabilities7,400.447,749.066,100.44
      Total Liabilities Growth (%)-4.5027.0215.22
      Total Equity7,911.376,773.506,696.60
      Total Equity Growth (%)16.801.1519.48
      Current Ratio (x)1.251.261.34
      Total Debt to Equity (x)0.580.810.60
      Contingent Liabilities288.52305.78365.47
      Annual FY 2024 FY 2023 FY 2022
      Total Assets9,550.888,042.407,208.32
      Total Assets Growth (%)18.7611.5725.22
      Total Liabilities2,838.812,780.612,140.98
      Total Liabilities Growth (%)2.0929.8829.28
      Total Equity6,712.075,261.795,067.34
      Total Equity Growth (%)27.563.8423.57
      Current Ratio (x)1.481.201.29
      Total Debt to Equity (x)0.170.310.22
      Contingent Liabilities190.29150.70101.97

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 434.01 cr for investing activities which is an YoY decrease of 67.58%. (Source: Consolidated Financials)
      Annual FY 2024 FY 2023 FY 2022
      Net Cash flow from Operating Activities1,004.54483.89766.42
      Net Cash used in Investing Activities-434.01-1,338.78-1,812.10
      Net Cash flow from Financing Activities-422.36817.79794.19
      Net Cash Flow165.96-31.95-176.79
      Closing Cash & Cash Equivalent219.1953.2385.18
      Closing Cash & Cash Equivalent Growth (%)311.78-37.51-67.48
      Total Debt/ CFO (x)4.5411.385.25
      Annual FY 2024 FY 2023 FY 2022
      Net Cash flow from Operating Activities358.2971.52255.20
      Net Cash used in Investing Activities-635.52-435.05-1,223.02
      Net Cash flow from Financing Activities451.38290.12905.74
      Net Cash Flow174.52-73.41-62.08
      Closing Cash & Cash Equivalent228.8054.2884.65
      Closing Cash & Cash Equivalent Growth (%)321.52-35.88-42.31
      Total Debt/ CFO (x)3.2122.754.32

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2024 FY 2023 FY 2022
      Return on Equity (%)0.22-2.755.61
      Return on Capital Employed (%)5.761.656.54
      Return on Assets (%)0.11-1.282.93
      Interest Coverage Ratio (x)3.062.486.18
      Asset Turnover Ratio (x)0.550.330.34
      Price to Earnings (x)1,000.00-43.86-
      Price to Book (x)2.161.21-
      EV/EBITDA (x)15.4015.66-
      EBITDA Margin (%)16.7812.0518.68
      Annual FY 2024 FY 2023 FY 2022
      Return on Equity (%)5.821.326.76
      Return on Capital Employed (%)8.394.048.61
      Return on Assets (%)4.090.864.75
      Interest Coverage Ratio (x)7.663.7911.59
      Asset Turnover Ratio (x)0.500.450.48
      Price to Earnings (x)43.67117.65-
      Price to Book (x)2.541.55-
      EV/EBITDA (x)21.9122.18-
      EBITDA Margin (%)18.6712.7320.06

    Financial InsightsPiramal Pharma

    • Income (P&L)
    • Cash Flow

      • Beating 3 Yr Revenue CAGR

        Company's annual revenue growth of 14.23% outperformed its 3 year CAGR of 8.72%. (Source: Consolidated Financials)

      • Employee & Interest Expense

        Company has spent 5.49% of its operating revenues towards interest expenses and 24.84% towards employee cost in the year ending Mar 31, 2024. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 434.01 cr for investing activities which is an YoY decrease of 67.58%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Piramal Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Piramal Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Piramal Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Piramal Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Piramal Pharma Technicals

    • Bullish / Bearish signals for Piramal Pharma basis selected technical indicators and moving average crossovers.

      5 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 17 Dec 2024

      5D EMA: 255.98

      Last 4 Buy Signals:29 Nov 2024
      Date7 days Gain/Loss %
      29 Nov 20245.64%
      24 Oct 20247.39%
      21 Oct 2024-0.30%
      15 Oct 20241.93%

      Average price gain of 4.37% within 7 days of Bullish signal in last 5 years

      10 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 17 Dec 2024

      10D EMA: 257.21

      Last 4 Buy Signals:29 Nov 2024
      Date7 days Gain/Loss %
      29 Nov 20245.64%
      24 Oct 20247.39%
      18 Oct 20241.87%
      15 Oct 20241.93%

      Average price gain of 3.99% within 7 days of Bullish signal in last 5 years

      Show More
    • 41%
      Positive Movement since
      1st Jan 2005 on basis
      58%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic270.38276.82290.07263.57257.13250.32237.07

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR12.1212.5112.34

    Piramal Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Piramal Pharma766.854.390.225.760.118.727.72-0.500.141.250.584.54
          Ipca Labs58.154.988.6412.444.9312.4814.126.8625.822.350.221.47
          Syngene Int.72.008.1511.9713.568.2916.5719.4614.6112.711.710.030.14
          Suven Pharma 133.0315.7714.6419.2413.322.8039.2928.5611.8011.820.020.11
          Laurus Labs234.837.483.907.941.911.548.313.332.981.230.613.77
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Gland Pharma
          • J B Chemicals
          • Emcure Pharmaceuticals Ltd.
          • Natco Pharma
          • Concord Biotech Ltd.

          Choose from Stocks

            See All Parameters

          Peers InsightsPiramal Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Piramal Pharma Shareholding Pattern

            • Loading...
              Showing Piramal Pharma Shareholding as on 30 Sep 2024
              Category30 Sep 202430 Jun 202431 Mar 202431 Dec 2023
              Promoters34.9534.9535.0235.02
              Pledge0.000.000.000.00
              FII31.7331.4030.5832.51
              DII13.8012.9512.129.68
              Mutual Funds11.2110.129.016.28
              Others19.5120.7022.2822.78
            • Showing Shareholding as on 30 Sep 2024
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters46,33,24,67234.95 %0.00
              Pledge00.00 %0.00
              FII42,06,94,90431.73 %0.32
              DII18,29,66,52813.80 %0.85
              MF14,86,81,01911.21 %1.09
              Others25,87,62,02619.51 %-1.18

            Piramal Pharma MF Ownership

            MF Ownership details are not available.

            Top Searches:
            Piramal Pharma News Piramal Pharma Quarterly Results Piramal Pharma Dividend Piramal Pharma Q1 ResultsPiramal Pharma Q2 ResultsPiramal Pharma Q3 ResultsPiramal Pharma Q4 Results

            Piramal Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              Oct 23, 2024Oct 14, 2024Board MeetingQuarterly Results
              Jul 26, 2024Jul 15, 2024Board MeetingQuarterly Results
              Jul 26, 2024Jun 11, 2024AGM-
              May 10, 2024Apr 30, 2024Board MeetingAudited Results & Final Dividend
              Jan 30, 2024Jan 17, 2024Board MeetingQuarterly Results
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Final1%0.11Jul 12, 2024May 10, 2024
            • All TypesEx-DateRecord DateAnnounced onDetails
              RightsAug 02, 2023Aug 02, 2023Feb 08, 2023Rights ratio: 5 share for every 46 held at a price of Rs 81.0

            About Piramal Pharma

            Piramal Pharma Ltd., incorporated in the year 2020, is a Small Cap company (having a market cap of Rs 34,549.00 Crore) operating in Pharmaceuticals sector. Piramal Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap and Other Operating Revenue for the year ending 31-Mar-2024. Show More

            • Executives

            • Auditors

            • NP

              Nandini Piramal

              Chairperson
              VV

              Vivek Valsaraj

              Executive Director & CFO
              PD

              Peter DeYoung

              Executive Director
              NB

              Neeraj Bharadwaj

              Non Executive Director
              Show More
            • Deloitte Haskins & Sells LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty Smallcap 100, Nifty 500, BSE 500, + 12 more

            Address

            Ground Floor, Piramal Ananta,Agastya Corporate Park,Kamani Junction,Mumbai, Maharashtra - 400070

            Contact

            [email protected]

            http://www.piramalpharma.com

            More Details

            FAQs about Piramal Pharma share

            • 1. What's Piramal Pharma share price today and what are Piramal Pharma share returns ?
              Piramal Pharma share price was Rs 262.85 as on 18 Dec, 2024, 02:13 PM IST. Piramal Pharma share price was up by 0.87% based on previous share price of Rs 251.25. Piramal Pharma share price trend:
              • Last 3 Months: Piramal Pharma share price moved up by 14.59%
              • Last 3 Years: Piramal Pharma Share price moved remain unchanged by N.A.
            • 2. What is the PE & PB ratio of Piramal Pharma?
              The PE ratio of Piramal Pharma stands at 762.17, while the PB ratio is 4.36.
            • 3. What are the returns for Piramal Pharma share?
              Return Performance of Piramal Pharma Shares:
              • 1 Week: Piramal Pharma share price moved up by 1.74%
              • 3 Month: Piramal Pharma share price moved up by 14.59%
            • 4. What are the Piramal Pharma quarterly results?
              Total Revenue and Earning for Piramal Pharma for the year ending 2024-03-31 was Rs 8346.55 Cr and Rs 17.82 Cr on Consolidated basis. Last Quarter 2024-09-30, Piramal Pharma reported an income of Rs 2302.86 Cr and profit of Rs 22.59 Cr.
            • 5. Who's the owner of Piramal Pharma?
              Promoter, DII and FII owns 34.95, 12.95 and 31.4 shares of Piramal Pharma as on 30 Sep 2024
              • There is no change in promoter holding from 30 Jun 2024 to 30 Sep 2024
              • Domestic Institutional Investors holding has gone up from 12.95 (30 Jun 2024) to 13.8 (30 Sep 2024)
              • Foreign Institutional Investors holding has gone up from 31.4 (30 Jun 2024) to 31.73 (30 Sep 2024)
              • Other investor holding have gone down from 20.7 (30 Jun 2024) to 19.51 (30 Sep 2024)
            • 6. What are the key metrics to analyse Piramal Pharma Share Price?
              Key Metrics for Piramal Pharma are:
              • PE Ratio of Piramal Pharma is 767.43
              • Price/Sales ratio of Piramal Pharma is 2.09
              • Price to Book ratio of Piramal Pharma is 4.37
            • 7. What is the market cap of Piramal Pharma?
              Piramal Pharma share has a market capitalization of Rs 34,761.12 Cr. Within Pharmaceuticals sector, it's market cap rank is 17.
            • 8. What has been highest price of Piramal Pharma share in last 52 weeks?
              In last 52 weeks Piramal Pharma share had a high price of Rs 307.90 and low price of Rs 114.35
            • 9. What is the CAGR of Piramal Pharma?
              The CAGR of Piramal Pharma is 6.65.
            • 10. Is Piramal Pharma a good buy?
              As per Refinitiv (erstwhile Thomson Reuters), overall mean recommendation by 5 analysts for Piramal Pharma stock is to Buy. Recommendation breakup is as follows
              • 2 analysts are recommending Strong Buy
              • 3 analysts are recommending to Buy
            • 11. Who are the peers for Piramal Pharma in Pharmaceuticals sector?
              Top 10 Peers for Piramal Pharma are Gland Pharma Ltd., Suven Pharmaceuticals Ltd., J B Chemicals & Pharmaceuticals Ltd., Natco Pharma Ltd., Laurus Labs Ltd., Emcure Pharmaceuticals Ltd., Syngene International Ltd., Ipca Laboratories Ltd., Alembic Pharmaceuticals Ltd. and Concord Biotech Ltd.

            Trending in Markets

            Top Gainers As on 02:17 PM | 18 Dec 2024

            KPR Mill1,145.45
            72.21 (6.73%)
            EID Parry977.50
            50.80 (5.49%)
            Mankind Pharma2,805.50
            143.70 (5.40%)
            Craftsman Automation5,347.90
            250.05 (4.91%)
            KFIN Technologies1,289.65
            53.75 (4.35%)

            Top Losers As on 02:16 PM | 18 Dec 2024

            NMDC211.90
            -15.61 (-6.87%)
            Deepak Fertilisers1,206.00
            -81.00 (-6.30%)
            Piramal Ent.1,151.75
            -73.21 (-5.98%)
            PVR1,412.05
            -82.55 (-5.53%)
            Bayer Cropsc.5,780.10
            -243.15 (-4.04%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Piramal Pharma Share Price
            The Economic Times
            BrowseCompanies: